MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 8071-8080 Newer>
The Motley Fool
November 21, 2011
Brian Orelli
This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday? mark for My Articles 57 similar articles
The Motley Fool
November 21, 2011
David Williamson
Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977. mark for My Articles 190 similar articles
The Motley Fool
November 19, 2011
Luke Timmerman
Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly. mark for My Articles 148 similar articles
The Motley Fool
November 18, 2011
Brian Orelli
Medtronic: Cutting Fat and Growing Margins The company announces that it has sold Physio-Control to private-equity fund Bain Capital. mark for My Articles 84 similar articles
The Motley Fool
November 18, 2011
Brian Orelli
This Biotech Stock Rose for All the Wrong Reasons Achillion Pharmaceuticals announces it might get bought and shares jump by as much as 17% today in response to the report, although it's pulled back a little since then. mark for My Articles 32 similar articles
The Motley Fool
November 17, 2011
Brian Orelli
In Biotech, Approval's Important, but It's the Launch That Counts With an approval in hand, Incyte's investors are still nervous. mark for My Articles 87 similar articles
The Motley Fool
November 15, 2011
Brian Orelli
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck. mark for My Articles 500 similar articles
The Motley Fool
November 15, 2011
Brian Orelli
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. mark for My Articles 106 similar articles
The Motley Fool
November 15, 2011
Selena Maranjian
Make Money in Biotech and Genome Stocks the Easy Way If you expect biotech firms and companies specializing in genomics to thrive as advances in health care and medicine continue, the PowerShares Dynamic Biotech & Genome ETF could save you a lot of trouble. mark for My Articles 703 similar articles
The Motley Fool
November 15, 2011
Dan Caplinger
Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares. mark for My Articles 870 similar articles
<Older 8071-8080 Newer>    Return to current articles.